Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loratadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 9/20 | 0.90 |
| ▸ | SLC6A15 | Q9H2J7 | 15/20 | 0.90 |
| ▸ | MEN1 | O00255 | 1/20 | 0.90 |
| ▸ | NPC1 | O15118 | 1/20 | 0.90 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.90 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.90 |
| ▸ | GMNN | O75496 | 1/20 | 0.90 |
| ▸ | USP2 | O75604 | 1/20 | 0.90 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.90 |
| ▸ | LMNA | P02545 | 1/20 | 0.90 |
| ▸ | TP53 | P04637 | 1/20 | 0.90 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.90 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.90 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.90 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.90 |
| ▸ | MAPT | P10636 | 1/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.90 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loratadine SCHEMBL3862958 | 0.95 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL29380223 | 0.95 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL29441811 | 0.95 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL4596 | 0.95 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL2166756 | 0.94 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL21529218 | 0.94 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL21529220 | 0.94 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL21529200 | 0.94 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL28594875 | 0.94 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL28800563 | 0.94 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122539-B2 | Nitric esters and nitrate salts of specific drugs | NICOX S.A. (FR) | 2006-10-17 | — | — | US | disclosed |
| US-6828342-B2 | Nitrate salts of Salbutamol, Cetirizine, Loratadine, Terfenadine, Emedastine, Ketotifen, Nedocromil, Ambroxol, Dextromethorphan, Dextorphan, Isoniazide, Erythromycin, and Pyrazinamide; respiratory system pathology treatment | NICOX, S.A. (FR) | 2004-12-07 | — | — | US | disclosed |
| US-20040132744-A1 | lower gastrointestinal and cardiovascular side effects; use in treatment of respiratory system disorders, as tokolitics and as antiallergics, for eye applications. | NICOX S.A. | 2004-07-08 | — | — | US | disclosed |
| US-20030028026-A1 | Nitric esters and nitrate salts of specific drugs | NICOX S.A. | 2003-02-06 | — | — | US | disclosed |
| US-6410791-B1 | SALBUTAMOL; RESPIRATORY SYSTEM DISORDERS | NICOX S.A. (FR) | 2002-06-25 | — | — | US | disclosed |
| EP-1098870-A2 | NITRIC ESTERS AND NITRATE SALTS OF SPECIFIC DRUGS | NICOX S.A. (FR) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000006531-A2 | NITRIC ESTERS AND NITRATE SALTS OF SPECIFIC DRUGS | NICOX S.A. (FR) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030028026-A1 | Nitric esters and nitrate salts of specific drugs | NOS3, NOS2, NOS1 | HRH1 1209/4885SLC6A15 418/4885MEN1 3378/4885 |
| US-20040132744-A1 | lower gastrointestinal and cardiovascular side effects; use in treatment of respiratory system disorders, as tokolitics and as antiallergics, for eye applications. | PTGIS, MGST3, TNNT2 | HRH1 430/4885SLC6A15 1117/4885MEN1 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.